 Failure ursodeoxycholic acid cholestatic episode patient benign recurrent intrahepatic cholestasis study bile acid metabolism Ursodeoxycholic acid patient benign recurrent intrahepatic cholestasis cholestatic episodes detailed study bile acid metabolism patient anicteric icteric phases ursodeoxycholic acid mg/day administration Urinary biliary serum bile acids gas chromatography-mass spectrometry high-performance liquid chromatography techniques anicteric phase daily urinary excretion serum concentrations bile acids normal ranges normal hepatic uptake secretion bile acids cholestasis-free period slight qualitative differences normal individuals relative proportions deoxycholic acid bile serum acid predominant urinary bile acid icteric phase marked increase urinary excretion primary bile acids metabolites Serum acid concentrations rise bilirubin acute disturbance bile acid transport onset cholestatic attack ursodeoxycholic acid administration anicteric phase bile exogenous bile acid little qualitative change metabolites present urine serum bile anicteric icteric phases Prolonged administration ursodeoxycholic acid recurrence cholestatic episode benign recurrent intrahepatic cholestasis oral ursodeoxycholic acid little benefit treatment prevention cholestasis marked enrichment bile acid pool hydrophilic bile acid